Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

Modulation of Post-COVID-19 Fatigue Using Transcranial Direct Current Stimulation. Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

Fatigue is common and disabling in patients with post-COVID syndrome. There is no treatment available at this moment, and fatigue has important consequences. The main aim of this study is to evaluate the changes in the severity of fatigue using non-invasive neuromodulation in patients with post-COVID condition. This is a randomized, parallel, double-blind, placebo-controlled clinical trial using transcranial direct current stimulation. Secondary aims include changes in cognition, depression, and quality of life.

Inclusion Criteria:

• Diagnosis of COVID-19 with PCR-confirmation.
• Fatigue linked to COVID-19
• No diagnosis of neurological, psychiatric or medical disorder with potential impact on fatigue.

Exclusion Criteria:

• Stroke before COVID-19
• History of traumatic brain lesion or central nervous system infection previous to COVID-19
• Radiotherapy or chemotherapy for cancer
• Severe sensorial deficits
• Drugs or uncontrolled medical disorder with potential impact on fatigue.
• History of abuse of alcohol or other toxics.
• Any contraindication for tDCS (metallic implants, brain devices, pacemakers, head injuries).